← Back to Search

Steroid

LPCN 1144 for Non-alcoholic Fatty Liver Disease

Phase 2
Waitlist Available
Research Sponsored by Lipocine Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 36
Awards & highlights

Study Summary

This study is evaluating whether LPCN 1144 is safe and tolerable in adults with NASH.

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 36
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 36 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measure the effect of LPCN 1144 on hematology panels
Measure the effect of LPCN 1144 on liver injury markers
Measure the effect of LPCN 1144 on serum lipid panels
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment AExperimental Treatment1 Intervention
LPCN 1144

Find a Location

Who is running the clinical trial?

Lipocine Inc.Lead Sponsor
6 Previous Clinical Trials
734 Total Patients Enrolled
1 Trials studying Non-alcoholic Fatty Liver Disease
56 Patients Enrolled for Non-alcoholic Fatty Liver Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Apr 2025